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We thank Dr. Shiels and co-authors for reading and commenting on our study.1,2
To summarize, we compared the age-adjusted incidence and mortality of 12,126 persons 
with chronic hepatitis C virus (HCV) infection in the Chronic Hepatitis Cohort Study 
(CHeCS) to Surveillance, Epidemiology and End Results Program (SEER) cancer registry 
data and to death certificate information from the Multiple Causes of Death (MCOD) 
database. We found that the incidence and mortality of many non-liver cancers were 
significantly higher in persons with HCV infection than in the comparison groups who 
approximate the US population.
We also found that the mean age of cancer diagnosis and cancer-related death was younger 
for persons with HCV infection in the CHeCS. These latter analyses were not age-adjusted 
and the subject of the comments of Shiels et al. With regard to the younger age at cancer 
diagnosis among HCV-infected CHeCS patients, our Methods indicate we used the SEER13 
database with exclusion of one of the 13 registries, the Alaska Natives registry. We did this 
to create a better comparison group for CHeCS: this “SEER12” more closely approximates 
the population of the other 49 states. In contrast, Shiels et al. compared our underlying 
population to SEER13. When we attempted to reproduce their analyses, but by comparing 
age of cancer diagnosis in CHeCS to SEER12, we found that the software developed to 
analyze data from SEER, called ‘SEER*STAT,’ (Surveillance Research Program, National 
Cancer Institute SEER*Stat software (seer.cancer.gov/seerstat) version 8.2.1) appears to lack 
the required functionality.
Specifically, age data can only be extracted from SEER13. There is no function to exclude a 
SEER registry (i.e. Alaska Natives) and then pull age data. We think this may be why Shiels 
et al. came to a different conclusion.
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Shiels et al. indicated a particular concern with the ≥64 year age group, the age group with 
the highest cancer incidence, and noted a smaller proportion of persons aged ≥64 in CHeCS 
(10%) versus SEER13 (19%). Using U.S. Census data corresponding to each SEER12 
registry (i.e., SEER 13 excluding Alaska Natives) and for the US overall, by age group, we 
found the percentage of persons 64 years or older for SEER was 11.8% and for the entire 
U.S. population was 14.6%. We think that given the large numbers of patients involved, 
these close percentages may represent a statistically significant difference between CHeCS 
and either SEER or the US population.
In considering the younger age of death among HCV-infected CHeCS cancer patients, it is 
helpful to remember that CHeCS patients have full ascertainment of their HCV infection, 
and analyses data from CHeCS and the MCOD show they die at a younger age compared 
with decedents without HCV infection.3,4 MCOD data –i.e., death certificates–only record 
19% of patients who actually have HCV infection at the time of death.3 In sum, HCV-
infected patients who develop cancer may indeed die at a younger age because of the 
contribution of both HCV infection and cancer to their morbidity and mortality.
As a practical matter, we think that cancer screening-related guidelines should be based on 
all available data including ours. Given our age-adjusted findings of increased cancer-related 
incidence and mortality among persons with chronic HCV infection, we think that both 
general clinicians and specialists should be aware of these elevated risks and take preventive 
action, such as facilitating tobacco and alcohol cessation and curing HCV with 
recommended antiviral therapy.
Sincerely yours,
Robert D. Allison, MD, MPH
Scott D. Holmberg, MD, MPH
Centers for Disease Control and Prevention Atlanta, GA, USA
Abbreviations
HCV hepatitis C virus
CHeCS Chronic Hepatitis Cohort Study (CHeCS)
SEER Surveillance, Epidemiology and End Results Program
MCOD Multiple Causes of Death (registry of death certificates)
SEER13 thirteen SEER cancer registries including: Atlanta, Connecticut, Detroit, 
Hawaii, Iowa, New Mexico, San Francisco-Oakland, Seattle-Puget Sound, 
and Utah, Los Angeles and San Jose-Monterey, Rural Georgia and the 
Alaska Native Tumor Registry
SEER12 all registries in SEER13, excluding the Alaska Native Tumor Registry
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